Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus

Journal of Atherosclerosis and Thrombosis

Volumn 14, Issue 2, 2007, Pages 86-93

  Teramoto, Tamio ^a   Yamada, Nobuhiro ^b   Shirai, Kohji ^c   Saito, Yasushi ^d  

^a TEIKYO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOHO UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

HDL C level; LDL particle size; Lipid and glycemic control; TG level

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

AGED; ARTICLE; ASIAN; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; SUBCUTANEOUS FAT; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 34250639039     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14.86     Document Type: Article

References (40)

1. Kaplan F, Al-Majali K, and Betteridge DJ: PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk, 2001; 8:211-217
2. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, and Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med, 1996; 334:952-957
3. Sunayama S, Watanabe Y, Daida H, and Yamaguchi H: Thiazolidinedienes, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol, 2000; 11:397-402
4. Gilling L, Suwattee P, DeSouza C, Asnani S, and Fonseca V: Effects of the thiazolidinedienes on cardiovascular risk factors. Am J Cardiovasc Drugs, 2002; 2:149-156
5. Proks P, Reimann F, Green N, Gribble F, and Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes, 2002; 51 (suppl 3):S368-376
6. Stumvoll M and Haring HU. Glitazones: Clinical effects and molecular mechanisms. Ann Med, 2002; 34:217-224
7. Gin H and Rigalleau V. Oral anti diabetic polychemotherapy in type 2 diabetes mellitus, Diabetes Metab, 2002; 28:350-353
8. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, and Burkey BF: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes, 2001; 50:1863-1871
9. Kaufman LN, Peterson MM, and DeGrange LM: Pioglitazone attenuates diet-induced hypertension in rats. Metabolism, 1995; 44:1105-1109
10. Hayakawa T, Shiraki T, Morimoto T, Shii K, and Ikeda H: Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun, 1996; 223:439-444
11. Ishida H, Kato S, Nishimura M, Mizuno N, Fujimoto S, Mukai E, Kajikawa M, Yamada Y, Odaka H, Ikeda H, and Seino Y: Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Horm Metab Res, 1998; 30:673-678
12. Lee CH, Olson P, and Evans RM: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 2003; 144:2201-2207
13. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, and Saruta T: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism, 2002; 51:314-317
14. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jimenez F, Hardin PA, Konkoy CS, and Tan MH: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther, 2003; 25:1074-1095
15. Miyazaki Y, Matsuda M, and DeFronzo RA: Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care, 2002; 25:517-523
16. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, and DeFronzo RA: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes, 2003; 52:1364-1370
17. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, and Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med, 2001; 111:10-17
18. Khan MA, St Peter JV, and Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care, 2002; 25:708-711
19. Harrower AD: Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf, 2000; 22:313-320
20. Hochberg Y and Tamhane AC: Multiple Comparison Procedures, John Wiley & Sons, 1987
21. Nichols AV, Krauss RM, and Musliner TA: Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol, 1986; 128:417-431
22. Miyashita Y and Shirai K: Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. Curr Med Chem Cardiovasc Hematol Agents, 2005; 3:377-381
23. Nakamura T and Matsuzawa Y: Insulin resistance syndrome, visceral fat syndrome. Nippon Rinsho, 1997; 55 (suppl):792-798
24. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, and Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Pioglitazone 001 Study Group. Diabetes Care, 2000; 23:1605-1611
25. Laakso M, Lehto S, Penttila I, and Pyorala K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation, 1993; 88:1421-1430
26. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, and DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 2002; 87:2784-2791
27. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, and Halimi S: Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care, 2000; 23:1679-1685
28. Gardner CD, Fortmann SP, and Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 1996; 276:875-881
29. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, and Krauss RM: Low-density lipoprotein sub-class patterns and risk of myocardial infarction. JAMA, 1988; 260:1917-1921
30. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, Welty TK, Lee ET, Krauss RM, and Howard BV: Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians: The Strong Heart Study. Arterioscler Thromb Vasc Biol, 1997; 17:2713-2720
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412-419
32. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, and Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 2000; 23:57-63
33. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, and Tan MH: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab, 2003; 88:1637-1645
34. Friedman JM and Leibel RL: Tackling a weighty problem. Cell, 1992; 69:217-220
35. Lowell BB: PPARγ: an essential regulator of adipogenesis and modulator of fat cell fimction. Cell, 1999; 99:239-242
36. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millio M, Berthault MF, Dugail I, Morin J, Auwerx J, and Ferre P: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes, 1997; 46:1393-1399
37. Lambe KG and Tagwood JD: A human peroxisome-proliferator-activated receptor γ is activated by inducers of adipogenesis, including thiazolidinediene drugs. Eur J Biochem 1996; 239:1-7
38. Smith U: Pioglitazone: mechanism of action. Int J Clin Pract, 2001; Suppl:13-18
39. Grossman LD: New solutions for type 2 diabetes mellitus: the role of pioglitazone. Pharmacoeconomics, 2002; 20 (suppl 1): 1-9
40. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, and Hawkins M: Mechanisms of early insulin-sensitizing effects of thiazolidinedienes in type 2 diabetes. Diabetes, 2004; 53:1621-1629